DLEU2L

Across TCGA pan-cancer cohorts, DLEU2L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DLEU2L data layer compared with 22 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DLEU2L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DLEU2L expression acts as an unfavorable survival marker.

PDAC, LSCC, and HNSC are the cancer types where DLEU2L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.677	0.874	.004	16	view →
LSCC	DFS	Median	All	0.858	1.000	.002	16	view →
HNSC	DFS	Tertile	III,IV	0.618	0.880	.003	10	view →
LUAD	OS	Tertile	II,III,IV	0.854	1.000	.016	5	view →
CCRCC	OS	Median	III,IV	0.485	1.000	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DLEU2L–PDAC (DFS)

Open the PDAC breakdown →